3 Live Webinars coming soon — Learn how to reduce risks in your raw materials supply chain - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

3 Live Webinars coming soon — Learn how to reduce risks in your raw materials supply chain


Supply chain security - how best to use the most important tool in supply chain protection

Infrared spectroscopy is the most economical way to screen against many of the risks that exist today in your supply chain of raw materials — counterfeit, contaminated, adulterated, diluted, substituted, false claims of purity/source etc.

Join us for a free webinar series to learn how PerkinElmer’s expertise can help improve your approach to supply chain security.

PROGRAM HIGHLIGHTS
These twenty minute webinars will be presented by our pharmaceutical IR application expert and will include a ten minute Q&A session to answer your specific questions or requests.
ATTEND ANY OF THE 3 WEBINARS AND DOWNLOAD YOUR COMPLIANCE RESOURCE KIT

1. Raw material identification in the Pharmaceutical industry. Why and how?
2nd October 2012 at 10:00 - 10:30am CET

2. Method development and instrument validation
9th October 2012 at 10:00 - 10:30am CET

3. Optimizing the performance of your instrument in IR Spectroscopy
16th October 2012 at 10:00 - 10:30am CET

PRESENTER: Kelly Palmer, Infrared Spectroscopy Pharmaceutical Specialist
MODERATOR: Gavin Aston, 'Safety & Security' Market Development Manager and U.K. & Ireland Analytical Sales Leader

WE PROMISE THAT YOU WILL:

  • Learn how to bring potential productivity improvements to existing and new infrared quality control procedures.
  • Find out how new best practices and techniques can reduce wastage and costs.
  • Enhance your personal and team knowledge and skills.

WHO SHOULD ATTEND THIS WEBINAR PROGRAM?
You should attend if you are a user, method developer, validation specialist or manager involved with infrared spectroscopy within a regulated laboratory.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here